<div id="readability-page-1"><p>Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 748,699 shares,  an increase of 17.0% from the March 31st total of 639,714 shares. Based on an average daily trading volume, of 260,064 shares, the days-to-cover ratio is currently 2.9 days. Currently, 4.7% of the company's shares are short sold.</p><div><p><span></span><span>Get <strong>Sutro Biopharma</strong> alerts:</span></p></div><h2>Sutro Biopharma Price Performance</h2><p>Sutro Biopharma stock opened at $35.39 on Thursday. The company's 50 day simple moving average is $25.39 and its 200 day simple moving average is $16.26. Sutro Biopharma has a fifty-two week low of $6.74 and a fifty-two week high of $36.60. The firm has a market capitalization of $586.34 million, a price-to-earnings ratio of -1.36 and a beta of 1.31. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts have recently commented on the stock. Leerink Partners assumed coverage on shares of Sutro Biopharma in a research report on Tuesday, April 7th. They set an &#34;outperform&#34; rating and a $38.00 price target for the company. Mizuho  set a $50.00 price target on shares of Sutro Biopharma in a research report on Thursday. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Sutro Biopharma from $51.00 to $55.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, March 25th. HC Wainwright upgraded shares of Sutro Biopharma from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price target for the stock from $10.00 to $28.00 in a research report on Tuesday, March 24th. Finally, Citizens Jmp lifted their price target on shares of Sutro Biopharma from $35.00 to $41.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Thursday, April 23rd. One equities research analyst  has rated the stock with a Strong Buy rating, seven have issued  a Buy rating, one  has issued  a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Sutro Biopharma presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $40.78.</p><p><b>Get Our Latest Research Report on Sutro Biopharma</b></p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. State of Tennessee Department of Treasury bought a new position in  Sutro Biopharma during the 4th quarter worth approximately $86,000.  Jane Street Group LLC bought a new position in  Sutro Biopharma during the 4th quarter worth approximately $265,000.  Bridgeway Capital Management LLC boosted its stake in  Sutro Biopharma by 232.6% during the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company's stock worth $37,000 after acquiring an additional 30,000 shares during the last quarter.  Bank of America Corp DE boosted its stake in  Sutro Biopharma by 51.3% during the 3rd quarter. Bank of America Corp DE now owns 119,434 shares of the company's stock worth $104,000 after acquiring an additional 40,488 shares during the last quarter.  Finally, Shay Capital LLC lifted its stake in  Sutro Biopharma by 20.1% in the third quarter. Shay Capital LLC now owns 312,051 shares of the company's stock valued at $271,000 after buying an additional 52,162 shares in the last quarter. Institutional investors own  96.99% of the company's stock. </p><h2>About Sutro Biopharma</h2> (Get Free Report)<p>Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.  </p><p>Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Sutro Biopharma</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sutro Biopharma Right Now?</h2><p>Before you consider Sutro Biopharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sutro Biopharma wasn't on the list.</p><p>While Sutro Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

STRO

LABU

<p>Sutro Biopharma, Inc. (NASDAQ:STRO) experienced a 17.0% increase in short interest in April, totaling 748,699 shares as of April 15th. The short-interest ratio is currently 2.9 days, with 4.7% of shares short sold. The stock opened at $35.39, with a market cap of $586.34 million. Analysts have given it an average rating of "Moderate Buy" with a target price of $40.78. Institutional investors own 96.99% of the stock, indicating strong institutional support for the company, which focuses on developing biologic drug candidates in oncology and immunology.</p>

Market Beat

Sutro Biopharma

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Mizuho Financial

Mizuho Financial Group, Inc.

Deutsche Bank AG

Citizens Financial

Bridge Investment

Bank of America

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0%